I'd like to come back to that in a minute, if I can.
Mr. Prouse, I want to go back to you first. In terms of some of these regulatory burdens, in your opening remarks and just now in your response, you mentioned specifically the PMRA, and you also mentioned the CFIA. I hear at different times from constituents and others about some of the challenges, particularly in comparison to the U.S. and how products there can be treated much differently than they are here, which therefore makes us uncompetitive against our U.S. neighbours.
Do you have any examples that you can share with us of that type of thing that you've seen in your organization?